1. Warning Letters and Regulatory Enforcement Actions
The FDA initiates most enforcement actions through a warning letter, which signals that the agency has identified violations during an inspection or investigation. When the agency issues a warning letter, the recipient typically has 15 business days to provide a written response outlining corrective actions. This is where disputes most frequently arise because the company must demonstrate not only that it has fixed the immediate problem but also that it has implemented systemic controls to prevent recurrence. The agency scrutinizes whether the response is credible and complete; a weak or evasive reply often accelerates the path to civil or criminal prosecution.
Failure to respond adequately within the deadline does not automatically trigger penalties, but it signals to the FDA that voluntary compliance is unlikely. The agency then evaluates whether to pursue injunction, seizure, or criminal referral. From a practitioner's perspective, the warning letter phase is the critical window for intervention. Many companies attempt to negotiate or seek an extension, but the FDA's position is typically rigid on the 15-day deadline unless extraordinary circumstances apply.
New York Federal Court Jurisdiction and Injunction Proceedings
When the FDA seeks to enforce compliance through an injunction, it typically files in federal district court, including the United States District Court for the Southern District of New York (SDNY) for companies operating in the Northeast. The court evaluates whether there is a reasonable likelihood that the FDA will succeed on the merits and whether the public interest favors an injunction. In practice, the FDA's burden is relatively low because courts recognize the agency's expertise and the public health rationale behind FDA regulatory enforcement. SDNY judges have consistently held that once the agency establishes a violation of the Food, Drug, and Cosmetic Act, an injunction is warranted unless the defendant can demonstrate that compliance is already underway and credible.
2. Civil Penalties, Seizure, and Administrative Remedies
Civil penalties under the Food, Drug, and Cosmetic Act can reach $100,000 per violation, and the FDA often counts each noncompliant unit or each day of noncompliance as a separate violation. This multiplier effect means that a single manufacturing defect affecting thousands of units can generate penalties in the millions. The FDA also has authority to seize products, which disrupts supply chains and can force a company into bankruptcy if the seized inventory is substantial.
Administrative remedies short of seizure include import detention and product holds. The FDA can detain imported products at the port of entry for up to 48 hours (extendable to 30 days) while it determines whether the shipment violates FDA standards. During this hold, the importer bears storage costs and faces operational delays. Many companies underestimate the commercial impact of a single detention; in global data compliance and cross-border regulatory risk scenarios, a hold on a shipment can cascade through supply agreements and trigger contractual penalties with downstream distributors.
Calculating Penalty Exposure and Mitigation Factors
The FDA considers several factors when assessing civil penalties: the nature and extent of the violation, the degree of culpability, the violator's history of prior violations, and the effect of the violation on public health. A company with a clean compliance record and a minor labeling error faces a substantially lower penalty than a repeat offender with systemic manufacturing defects. The agency also weighs whether the company discovered the violation and reported it voluntarily. Voluntary disclosure often reduces penalties by 50 to 75 percent, provided the company acts before the FDA initiates its own investigation.
| Violation Category | Typical Penalty Range | Aggravating Factor |
| Labeling defect (single product) | $5,000 to $15,000 | Prior warning letter |
| Manufacturing process failure | $30,000 to $75,000 | Public health risk |
| Knowing violation (criminal referral) | Criminal fines plus imprisonment | Intent to defraud |
3. Criminal Prosecution and Knowing Violations
The FDA can refer cases to the Department of Justice for criminal prosecution when there is evidence of knowing violation. A "knowing" violation does not require proof of intent to harm; it means the defendant acted with knowledge that the conduct violated the law, even if the defendant believed the violation was minor or unlikely to be detected. Criminal penalties include fines up to $250,000 and imprisonment up to 10 years for individuals, and corporate fines up to $1 million. Prosecution is rare but increasingly common in cases involving intentional mislabeling, adulteration, or falsification of testing records.
Criminal cases involving FDA regulatory violations typically begin with a grand jury investigation and subpoena of company records. Once a subpoena arrives, the company should immediately retain counsel experienced in white-collar defense. Cooperation and early disclosure of internal findings can reduce criminal exposure significantly, but any statement made to government investigators without counsel present can be used against the company or its officers. The calculus shifts dramatically once criminal exposure enters the picture.
4. Strategic Response to Enforcement Actions
When a company receives a warning letter or learns of an FDA inspection, the immediate priority is assembling a response team that includes quality assurance, legal counsel, and senior management. The response must be specific, not generic. Vague commitments to "improve compliance" or "enhance training" do not satisfy the FDA. The agency expects detailed root cause analysis, identification of all affected products, a timeline for corrective action, and evidence of management commitment.
Engaging FDA regulatory counsel before submitting a response is critical. An attorney can assess whether voluntary disclosure or negotiation is feasible, whether the company should request a meeting with the FDA to discuss the response, and whether the violations warrant disclosure to customers or regulatory authorities in other jurisdictions. In complex cases involving global data compliance and cross-border regulatory risk, the company may face simultaneous enforcement actions in multiple countries, requiring a coordinated strategy.
The decision whether to contest an FDA enforcement action, seek settlement, or pursue litigation depends on the strength of the company's defenses, the magnitude of penalties at stake, and the reputational impact of prolonged dispute. Most companies settle within 12 to 18 months of receiving a warning letter, but early legal assessment can identify cases where the FDA's position is vulnerable or where negotiated resolution is achievable.
14 Aug, 2025
